Estimating the burden of illness related to genital warts in the Philippines: a nationally representative cross-sectional study.

Autor: Buenconsejo L; 1Makati Medical Center, Makati, Philippines., Kothari-Talwar S; 2Merck & Co. Inc., Kenilworth, NJ USA., Yee K; 3Cubist Pharmaceuticals, Lexington, MA USA., Kulkarni A; 2Merck & Co. Inc., Kenilworth, NJ USA., Lara N; IMS Health, Barcelona, Spain., Roset M; IMS Health, Barcelona, Spain., Giuliano AR; 5Center for Infection Research in Cancer (CIRC) at Moffitt Cancer Center, Tampa, FL USA., Garland S; 6Royal Women's Hospital, Melbourne, Australia.
Jazyk: angličtina
Zdroj: Infectious agents and cancer [Infect Agent Cancer] 2019 Oct 07; Vol. 14, pp. 26. Date of Electronic Publication: 2019 Oct 07 (Print Publication: 2019).
DOI: 10.1186/s13027-019-0240-y
Abstrakt: Background: This study estimated genital warts prevalence, genital-warts-related healthcare resource use and costs, and self-reported human-papillomavirus-related psychosocial impact among male and female patients aged 18-60 years in the Philippines.
Methods: Prevalence was estimated using daily logs numbering genital warts patients treated by participating physicians in 4 Philippine regions over a 5-week period (09JUL2011-24SEP2012). Physicians also completed a survey assessing patient referral patterns, healthcare resource use, treatment, and follow-up care. Psychosocial impact was estimated using the human papillomavirus impact profile and the EQ-5D questionnaires. HIP and EQ-5D scores were compared according to the presence of GW (males) and HPV disease (females). CECA scores were also compared by gender and age groups.
Results: Overall genital warts prevalence was estimated at 4.78% (95% confidence interval [CI]: 4.58-4.98%) for men and women aged 18-60 years. Genital warts prevalence was 3.39% (95% CI: 3.13-3.65%) and 8.0% (95% CI: 7.69-8.31%) among women and men, respectively. Prevalence estimates were highest in infectious disease specialist practices 18.67% (95% CI: 18.66-18.69%). Two thirds of the 233 (69.14%) male and 166 (67.20%) female patients were newly-diagnosed genital warts cases. Median costs for genital warts diagnosis and treatment reached 7121 and 7000 Philippine pesos among men and women, respectively. In the Cuestionario Específico para Condiloma Acuminado questionnaire, no statistically significant differences between patients were observed. In the EQ-5D questionnaire, male genital warts patients reported lower mean visual analogue scale scores than those without genital warts (78.20 vs 86.34, p  < 0.0001). Mean visual analogue scale score values and utility values were lower for women with human-papillomavirus-related diseases than those without (77.98 vs 78.93, and 0.84 vs 0.88, respectively).
Conclusions: Genital warts is prevalent in the Philippines; more than 60% of cases were newly diagnosed, contributing to high genital-warts-related healthcare resource costs. Diagnosis of genital warts and human papillomavirus negatively impacted psychosocial indices such as patient well-being and health-related quality of life.
Competing Interests: Competing interestsLB declares they have no conflicts to disclose. AK and SKT are employees of Merck & Co. SMG received grants to her institution from: the Commonwealth Department of Health for human papillomavirus (HPV) genoprevalence surveillance post-vaccination; Merck & Co. and GSK to perform phase 3 clinical vaccine trials; Merck & Co. to evaluate HPV in a post-vaccination program; Commonwealth Serum Laboratories for an HPV in cervical cancer study; and the Veterinary Centers of America for a study on the effectiveness of a public health HPV vaccine and a study on the associations of early onset cancers. SMG also received speaking fees from Merck Sharp and Dohme Corp., and Sanofi Pasteur/Merck Sharp and Dohme for work performed in her personal time. Merck & Co. paid for travel and accommodations to present at HPV Advisory board meetings. KY was a paid contractor for Merck & Co. at the time of the study and was an employee of Cubist Pharmaceuticals from December 2014 to July 2015, which was acquired by Merck & Co. in January 2015. ARG is a member of Merck & Co. advisory boards. Her institution has received grants and contracts to support HPV-related research. NL and MR are employees of IMS Health, Barcelona, Spain, which is a paid consultant to Merck & Co.
(© The Author(s). 2019.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje